US Patent

US8133893 — Trazodone and trazodone hydrochloride in purified form

Composition of Matter · Assigned to Aziende Chimiche Riunite Angelini Francesco ACRAF SpA · Expires 2029-03-13 · 3y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a process for producing trazodone or trazodone hydrochloride with low levels of an alkylating substance.

USPTO Abstract

A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
US8133893
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-03-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.